Abstract: Schizophrenia and bipolar disorder are severe psychiatric disorders that are frequently associated with persistent symptoms and significant dysfunction. While there are a multitude of psychopharmacologic agents available for treatment of these illnesses, suboptimal response and significant adverse consequences limit their utility. Cariprazine is a novel antipsychotic medication with dopamine D2 and D3 partial agonist effects. Its safety and efficacy have been investigated in acute psychosis of schizophrenia, bipolar mania, bipolar depression, and unipolar depression. Efficacy has been demonstrated in schizophrenia and mania. It is unclear if cariprazine is effective in depression associated with unipolar or bipolar illness. Adverse consequences include extrapyramidal symptoms including akathisia, and various gastrointestinal symptoms. The US Food and Drug Administration (FDA) has recently approved cariprazine. This review will provide clinicians with basic information regarding the research program of cariprazine.

Keywords: cariprazine, dopamine D3 receptor, dopamine D2 receptor, bipolar disorder, mania, bipolar depression, schizophrenia

Introduction

Schizophrenia is a severe and persistent mental illness and treatment is woefully inadequate for the majority of afflicted individuals. Nearly all available antipsychotic agents are dopamine D2, D3, and/or D4 receptor antagonists. More recently, partial agonistic action at D2 and D3 receptors has suggested that this may be a promising approach. Three partial agonist compounds have now been approved for acute psychosis associated with schizophrenia by the US Food and Drug Administration (FDA): aripiprazole, brexipiprazole, and cariprazine. The newest of these, cariprazine, has unique properties that may affect its clinical profile.

Similarly, bipolar illness is a severe, recurring illness. While psychosis is a common symptom in manic and depressed individuals with bipolar I disorder, antipsychotic agents have demonstrated efficacy independent of the presence of psychosis. Furthermore, antipsychotics with antidepressant potential have helped fulfill an unmet need for bipolar patients. Cariprazine has been studied in this population as well.

Cariprazine is a piperazine derivative that was developed by Geoden-Richter in Hungary. Initially, scientists identified trans-N-[4-[4-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl][ethyl]cyclohexyl]-N,N'-dimethylurea hydrochloride or “2m” as an impurity in biosynthetic experiments. However, subsequent analysis revealed that this impurity was more promising than the original research target. The drug was subsequently named cariprazine (RGH-188) and investigated clinically for both schizophrenia and depression in unipolar and bipolar illness.
Pharmacodynamics and pharmacokinetics

Cariprazine is a partial agonist at the dopamine D2 and D3, and the serotonin 5HT1A receptors. It has high affinity to these receptors (Ki = 0.5, 0.085, and 3.0 nM, respectively) as well as serotonin 5HT2B and 5HT2A receptors. At doses approaching 2–3 mg per day, cariprazine receptor occupancy easily exceeds 85% for D2 and D3 receptors in monkeys. In humans with schizophrenia, 1.5 mg daily will achieve 69%–75% receptor occupancy. In nonpsychotic controls, doses of 1 mg daily achieve over 65% receptor occupancy. Serotonin 5HT1A receptor occupancy never exceeds 30% despite a high affinity. Cariprazine is safe and effective in dose ranges 3–12 mg daily.

The half-life of cariprazine is ~2–6 days. Cmax for cariprazine is achieved in 3–4 hours after an oral dose, but because of a half-life of 2–6 days, achieves steady state in over a week. Furthermore, it has two active metabolites, desmethyl-cariprazine and didesmethyl-cariprazine, which prolong time to functional steady state to over 1 month. Metabolism occurs through CYP450 3A4 and, to a lesser extent, CYP450 2D6.

Partial dopamine agonist antipsychotics allow clinicians to obtain clinical efficacy while minimizing dopamine-related adverse events (AEs). Dopamine-mediated AEs occur when receptor occupancy exceeds 80% in both animals and humans. This is so close to the 65% D2 occupancy which is required to achieve the antipsychotic effect that it is difficult to titrate the dose appropriately, and clinicians generally use antipsychotics at 90% occupancy.

Cariprazine, and other high-affinity partial agonists, solve this problem. When cariprazine is administered at a dose that occupies 95% of the D2 receptors, the partial activation produces an apparent lower level of blockade. The level of partial activation needs to mimic the natural tonic dopamine signal in the brain, ~20%–25% of the maximal dopamine signal. Thus, partial agonists must stimulate the D2 receptor at a level similar to this. Cariprazine may reduce the risk of dopamine-related AEs even further due to its partial agonistic effect on 5HT1A, which may reduce extrapyramidal symptoms and improve mood and cognition.

The reduction of D2-mediated AEs is essentially quantified in the serum prolactin data. In long-term safety studies in patients with schizophrenia, mean prolactin levels drop by 18.3 ng/mL at 48 weeks versus baseline (dose range from 1.9 to 9 mg/day). While some of this reduction may be related to some of the patients coming off a prolactin-increasing antipsychotic, the reduction is consistent with the activation of D2 receptors at/near the natural tonic level of dopamine by the partial agonist effect of the drug.

Partial agonism may also play an important role that is specific to the pathophysiology of schizophrenia. Recent positron emission tomography studies suggest that patients with early or chronic schizophrenia have an increase in dopamine synthesis and dopamine release. However, the synaptic density is unchanged versus controls, suggesting that the amount of dopamine per synapse in patients with schizophrenia is increased. Indeed, there is evidence that in subjects with schizophrenia and at-risk individuals, the dopamine system is hyperresponsive. A high-affinity partial agonist will fully prevent endogenous dopamine from interacting with postsynaptic receptors while creating a partial dopamine signal that normalizes functional dopamine signal.

Cariprazine is generally described as a D3-prefering agent. The D3 receptor has the highest density of expression in the nucleus accumbens and olfactory tubercle. Overexpression of D3 reduces motivation in mice, and blockade of D3 improves cognition and reduces hyperactivity in rats. While antipsychotics frequently block D3, and a genetic variant of this receptor has been associated with risk of developing tardive dyskinesia, cariprazine is a partial agonist, so that some stimulation of the receptor continues even at maximal receptor occupancy. As would be expected from the receptor profile, cariprazine has demonstrated efficacy in animal models that examine cognition, depression, and mania.

Cariprazine in schizophrenia

Four acute studies performed in subjects with schizophrenia have either been published directly, or presented in meetings and published in review format. In an early Phase II study, 392 subjects with acute schizophrenic psychosis were randomized to receive 1.5–3 mg/day or 3–6 mg/day of cariprazine or placebo, after a 7-day washout, and followed for 6 weeks. A large fraction (46%) discontinued the study early for a variety of reasons. A larger fraction of patients receiving placebo (15%) stopped the study for lack of efficacy than in either active arm (8% in the low-dose arm and 9% in the high-dose arm). The score of the Positive and Negative Syndrome Scale (PANSS) improved significantly in patients receiving 1.5–3 mg/day of cariprazine compared to placebo; the higher dose arm did not statistically separate from placebo.

A second Phase II study which has been published randomized 732 subjects with acute schizophrenic psychosis to one of five arms: cariprazine 1.5 mg/day, 3 mg/day,
4.5 mg/day, placebo, or risperidone 4 mg/day for 6 weeks. All active arms improved significantly compared to placebo. There appeared to be a dose-related change in magnitude of PANSS change with a least squares mean difference (LSMD) of \(-7.6, -8.8, \) and \(-10.4\) for 1.5, 3, and 4.5 mg/day of cariprazine, respectively; risperidone change was \(-15.1\), but the study was not powered to examine differences in the active arms.\(^{40}\)

A Phase III study randomized 617 patients to cariprazine 3 mg/day or 6 mg/day, aripiprazole 10 mg/day, or placebo. All active arms improved significantly compared to placebo. The cariprazine 6 mg/day arm and aripiprazole group separated from placebo at week 1; the low-dose cariprazine arm separated from placebo at week 3 (due to the long half-life and delay in reaching steady state).\(^{38}\)

A second Phase III study randomized 446 people with acute schizophrenia to three arms: cariprazine 3–6 mg/day (n=151), cariprazine 6–9 mg/day (n=1,480), and placebo (n=147).\(^{37}\) Both active arms improved significantly relative to placebo, but again there appeared to be a numerical dose effect with LSMD of \(-6.8\) for the low-dose arm and \(-9.9\) for the high-dose arm.\(^{37}\)

Across the three published schizophrenia studies, males outnumbered females by a ratio of approximately 3:1.\(^{37,38,40}\) There were no reported differences in efficacy or AEs between the sexes.

In summary, short-term studies performed with cariprazine in patients with acute exacerbation of schizophrenia revealed the drug to be effective in a wide range of doses, and revealed that the extent of improvement is similar to established second-generation antipsychotics. There may be evidence of dose-responsiveness in the antipsychotic effect. This may be a true pharmacodynamics effect, or may be related to a pharmacokinetic effect where lower doses require a longer time to reach levels achieved at higher doses, and steady-state levels are not achieved in the brief 6-week period.

The side-effect profile in both the short-term and long-term studies was similar for patients with bipolar illness and patients with schizophrenia. The safety profile of cariprazine is discussed in the following section.

**Efficacy in bipolar illness**

Three randomized controlled trials have been conducted in patients with mania.\(^{38,41}\) A Phase II study randomized 238 adults to either a flexible-dose cariprazine (3–12 mg/day) or placebo.\(^{41}\) The majority of patients (66.1\%) reached 12 mg/day, and the average dose was 8.8 mg/day.\(^{41}\) The LSMD by week 3 was \(-6.12\) points on the Young Mania Rating Scale (YMRS) (Figure 1). Approximately, half of the patients (48\%) achieved at least a 50\% improvement, or became euthymic (42\%) compared to one-quarter of placebo-treated patients (25\% and 23\%, respectively).\(^{37,41}\) As with nearly all of the cariprazine studies, dropout rates were high, so that 61.9\% (n=73) of the placebo group and 63.6\% (n=75) of the cariprazine group completed the study.\(^{37,41}\)

Two Phase III trials with manic patients have been presented. The first trial randomized 312 acutely manic adults to either a flexible-dose cariprazine or placebo. Over half of the patients responded (59\%) or achieved remission (52\%) on cariprazine compared to significantly smaller numbers on placebo (44\% and 35\%, respectively).\(^{42}\) The LSMD in YMRS score was \(-4.3\) for the cariprazine-treated patients.\(^{42}\)

In the second Phase III trial, 497 manic patients with mania were randomized to cariprazine 3–6 mg/day, 6–12 mg/day, or placebo.\(^{43}\) The YMRS LSMD was essentially the same for both dose ranges (\(-6.1\) points for the lower dose and \(-5.9\) points for the higher dose, both \(P<0.001\)).\(^{43}\) Only 25\% of patients in this study achieved remission.

Cariprazine was also investigated as a potential antidepressant in depressed patients with bipolar and unipolar disorders. In a Phase II study, 233 depressed subjects with bipolar disorder were randomized to a very-low-dose arm (0.25–0.75 mg/day), a low-dose arm (1.5–3.0 mg/day), and placebo. There was no statistically significant separation from placebo.\(^{44}\) In a subsequent study, 584 depressed patients with bipolar disorder were treated for 8 weeks with cariprazine 0.75 mg/day, 1.5 mg/day, 3.0 mg/day, or placebo.\(^{45}\) The group receiving 1.5 mg of cariprazine improved transiently at week 6 (four-point improvement on Montgomery–Åsberg Depression Rating Scale, \(P=0.003\)).\(^{45}\) These findings mirror other
Safety and tolerability

Cariprazine has been approved for use in patients with acute exacerbation of schizophrenia and bipolar mania (including mixed states). The AE profile in the short-term studies in schizophrenia and bipolar disorders is very similar. 38–41,51–54

While the efficacy of cariprazine appears to be dose-related, so that doses of 3.0–4.5 mg once daily are generally more effective than lower doses, tolerability does not appear to be dose-related. 40 In most acute studies, more placebo-treated subjects compared to cariprazine discontinued treatment due to insufficient therapeutic response. 40 Compared to other FDA-approved second-generation atypical antipsychotics, cariprazine is less likely to produce clinically significant metabolic side effects, such as weight gain, hyperlipidemia, hypercholesterolemia, and hyperglycemia, with any observed changes being similar to placebo. 37,40,55 There are no significant ECG abnormalities 55 and prolactin levels usually drop. 55 Common AEs are either central (in order of decreasing frequency: insomnia, extrapyramidal symptoms, akathisia, sedation, dizziness, and anxiety) or gastrointestinal (nausea, constipation, and vomiting). 7,40,41 In patients with bipolar illness, measuring akathisia (utilizing the Barnes Akathisia Rating Scale) reveals a nonsignificant increase in akathisia with cariprazine versus placebo (0.4 vs 0.09, \(P=0.12\)). 41 However, when parkinsonism is measured by the Simpson Angus Scale, there is a significantly greater level of extrapyramidal symptoms in patients receiving cariprazine (1.17) versus placebo (0.09, \(P<0.01\)). 41 In most studies, AEs did not appear to be dose related. 31,55 However, in one unpublished acute mania study, AEs occurred at greater frequency at higher doses (6–12 mg/day) compared to lower doses (3–6 mg/day), and both greater than placebo. 7

There were no reported abnormalities in liver function or P450 enzyme function with cariprazine treatment. However, due to the long half-life of the drug and its equipotent active metabolites, the FDA added a warning that cariprazine may have late-occurring AEs, occurring after weeks of treatment.

In summation, cariprazine was considered safe and well tolerated among adult patients diagnosed with acute schizophrenia and bipolar mania.

Conclusion

Partial agonists of the dopamine system are becoming the preferred class of medications over pure antagonists in treatment of both psychosis and mood disturbance. This is because tolerance to the medication is less likely to occur when the receptor is both blocked and stimulated at the same time. Cariprazine is a partial agonist at D2, D3, and 5HT1A receptors. The affinity at the D3 receptor is approximately six times greater than at the D2 receptor. However, it is administered at a dose that generally blocks the majority of both of these receptors.

Studies with partial agonists, particularly with long half-lives are frequently difficult to predict, and this appears to be the case with cariprazine. In studies with patients with bipolar mania or schizophrenic psychosis, cariprazine has shown significant efficacy and a tolerable AE profile. However, it is much more difficult to interpret the depression data. The data are consistent with the interpretation of a window in which the drug may be effective with depression, in a manner similar to aripiprazole and brexpiprazole. The task of understanding the effect of the drug is made more difficult by the paucity of publications of the completed clinical trials. Nonetheless, the recent approval of cariprazine provides a new tool for clinicians, which appears to have unique mechanistic profile.

Disclosure

Dr Rif S El-Mallakh has grant funding from the National Institute of Mental Health, the State of Kentucky, Merck,
Teva, and Psychiontics; and is a speaker for Allergan, Lundbeck, Merck, Otsuka, Sunovion, and Takeda. He reports no other conflicts of interest in this work. The other authors report no conflicts of interest in this work.

References